GRM3: Metabotropic glutamate receptor 3
G protein-coupled receptor for glutamate.
- Drugs that act on it: 4
- Approved: 0
- In phases 1 to 3: 4
- Sponsors: 2
Who is on it, and how far along
Every drug ChEMBL records acting on GRM3, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 3
- Other 1
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- Denovo Biopharma LLC125%
- Roche125%
| Pomaglumetad methionil anhydrous | Phase 3 | Denovo Biopharma LLC | Small molecule | Agonist | 0 |
| Decoglurant | Phase 2 | Roche | Small molecule | ModulatorMetabotropic glutamate receptor 3 modulator | 0 |
| LY2969822 | Phase 1 | — | Other | Agonist | 0 |
| LY404039 | Phase 1 | — | Small molecule | Agonist | 0 |
- Schizophrenia0.61
- Hearing loss disorder0.49
- Bipolar disorder0.44
- Mathematical ability0.43
- Neurotic disorder0.42
- Abnormality of the skeletal system0.41
- Autism spectrum disorder0.40
- Smoking initiation0.39
- Major depressive disorder0.35
- Alcohol drinking0.35
- Anxiety0.34
- Intelligence0.33
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2888, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q14832, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets